Evidence map›Paper›PMID 19915630›Full record

ArticleBone marrow transplantation2010

Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.

D-Y Kim, J-H Lee, J-H Lee, S-H Kim, S-N Lim, S-D Kim, Y Choi, Y-S Lee, Y-A Kang, S-I Kang and 3 more

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Understanding chronic GVHD from different angles.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

D-Y KimDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
J-H Lee
J-H Lee
S-H Kim
S-N Lim
S-D Kim
Y Choi
Y-S Lee
Y-A Kang
S-I Kang
M Seol
S-G Ryu
K-H Lee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-alone' patients, we re-categorized 216 patients in keeping with the NIH criteria. Twenty patients were reclassified as having acute GVHD and 196 patients as having cGVHD (170 'classic chronic' (Cl-Ch) and 26 'overlap chronic' (Ov-Ch)). The 5-year GVHD-specific survival (GSS) was significantly different between the two cGVHD subtypes, specifically 87.3% for Cl-Ch vs 70.2% for Ov-Ch (P=0.006). The NIH severity criteria were effective in expecting 5-year GSS rates at both the onset (93.5, 81.3 and 79.7% (P=0.047)) and peak intensity of the disease (100, 89.7 and 78.7% (P=0.004) for the mild, moderate and severe grade, respectively). Multivariate analysis showed that NIH severity criteria were independently significant prognostic factors for GSS (mild vs moderate, HR 4.35, P=0.036; mild vs severe, HR 5.25, P=0.020). Our results support the role of the NIH criteria in classifying cGVHD and in assessing the severity of the disease to predict patient prognosis of cGVHD.

Indexed as

Chronic DiseaseClassificationGraft vs Host DiseaseHumansNational Institutes of Health (U.S.)Practice Guidelines as TopicPrognosisSeverity of Illness IndexSurvival RateUnited States

Identifiers

PMID19915630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.